Stage IV non-small cell lung cancer (NSCLC) is incurable with 5-year survival rates of less than 5% with platinum doublet chemotherapy, however, targeting PD-1/PD-L1 improved overall survival (OS) up to 30 [1]. Here, CD274 is linked to non-small cell lung carcinoma.